Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31441479 | 1.00 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTGAACYP1A2 | |
| SCHEMBL22439450 | 0.94 | ALDH1A1 (0.51) | ALDH1A1LMNAMAPTGAACYP1A2 | |
| SCHEMBL22370558 | 0.94 | ALDH1A1 (0.51) | ALDH1A1LMNAMAPTGAACYP1A2 | |
| SCHEMBL17848342 | 0.87 | ALDH1A1 (0.57) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 | |
| SCHEMBL31441688 | 0.85 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTGAACYP1A2 | |
| SCHEMBL22346052 | 0.83 | ALDH1A1 (0.58) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 | |
| SCHEMBL17848404 | 0.82 | ALDH1A1 (0.62) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 | |
| SCHEMBL17848607 | 0.81 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTGAACYP1A2 | |
| SCHEMBL22346876 | 0.81 | ALDH1A1 (0.58) | ALDH1A1LMNAMAPTCYP1A2CYP2D6 | |
| SCHEMBL31316605 | 0.81 | ALDH1A1 (0.60) | ALDH1A1LMNAMAPTGAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-08-28 | — | — | US | disclosed |
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-04-17 | — | — | US | disclosed |
| WO-2025054448-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | SATELLOS BIOSCIENCE INC. (CA) | 2025-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122207-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, CAMKK1, AP2A1 | ALDH1A1 3638/4885LMNA 2115/4885MAPT 1810/4885 |
| US-20250270222-A1 | AP2 ASSOCIATED KINASE 1 INHIBITORS AND USES THEREOF | AAK1, AP2A1, CSNK1A1 | ALDH1A1 3210/4885LMNA 3437/4885MAPT 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.